Actuate Therapeutics, Inc.

ACTU Nasdaq SEC CIK 1652935
Follow Actuate Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$3.4M +36.7% vs same quarter last year
EPS, diluted −$0.14 +44% vs same quarter last year
Operating cash flow −$3M +55.8% vs same quarter last year
Operating income −$3.4M +37.2% vs same quarter last year
Net income by quarter
−$6.4M
−$6.3M
−$5.9M
−$5.4M
−$4.6M
−$5.6M
−$4.9M
−$3.4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
−$30M−$20M−$10M$0FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$22.2M
FY24−$27.3M
FY23−$24.7M
FY22-